Last reviewed · How we verify

GEMIGLIPTIN LS15-0444 — Competitive Intelligence Brief

GEMIGLIPTIN LS15-0444 (GEMIGLIPTIN LS15-0444) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

GEMIGLIPTIN LS15-0444 (GEMIGLIPTIN LS15-0444) — Sanofi. Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GEMIGLIPTIN LS15-0444 TARGET GEMIGLIPTIN LS15-0444 Sanofi phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4)
SGLT2i+Metformin+Cofrogliptin SGLT2i+Metformin+Cofrogliptin Huazhong University of Science and Technology marketed SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination) SGLT2, mitochondrial complex I, DPP-4
Pioglitazone + Alogliptin Pioglitazone + Alogliptin Celltrion Pharm, Inc. marketed Thiazolidinedione + DPP-4 inhibitor combination PPAR-γ and DPP-4
MET + Vildagliptin Group MET + Vildagliptin Group Hospital de Clinicas de Porto Alegre marketed Combination antidiabetic agent (biguanide + DPP-4 inhibitor) Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Januvia (sitagliptin) Januvia (sitagliptin) Zealand University Hospital marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4)
oral hypoglycemic agents oral hypoglycemic agents Queen Elizabeth II Health Sciences Centre marketed Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Incretin-based therapy Incretin-based therapy Nagaoka Red Cross Hospital marketed Incretin mimetic or DPP-4 inhibitor GLP-1 receptor or DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

  1. Merck Sharp & Dohme LLC · 5 drugs in this class
  2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. LG Life Sciences · 2 drugs in this class
  5. Tanabe Pharma Corporation · 2 drugs in this class
  6. Ain Shams University · 2 drugs in this class
  7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
  8. Cinnagen · 1 drug in this class
  9. GRADE Study Group · 1 drug in this class
  10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GEMIGLIPTIN LS15-0444 — Competitive Intelligence Brief. https://druglandscape.com/ci/gemigliptin-ls15-0444. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: